GPR55 and peripheral neuropathy: Our current therapeutic interest is in the development of the novel cannabinoid KLS-13019 as a GPR55 antagonist that can prevent and reverse chemotherapy-induced peripheral neuropathy (CIPN) (Foss et al., 2021; Ippolito et al., 2024).